{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:38:18Z","timestamp":1785577098669,"version":"3.56.0"},"reference-count":87,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2021,7,22]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>Psoriatic arthritis (PsA) affects approximately 0.8% of the general population. PsA, together with psoriasis (PsO), constitute psoriatic disease (PsD). Comorbidities play an important role in the clinical expression and treatment of PsD. Aging adds another level of complexity, partly because age directly accrues increasing risk of comorbidities, but also because of its complex interactions with several factors such as depression and social determinants. Aging seems to have a \u201cparadoxical association\u201d with cardiovascular comorbidities, for which the relative risk is more pronounced in younger patients with PsD. It also affects treatment decisions and treatment response in patients with PsD. Finally, there is convincing evidence that there are clinical, genetic, and histopathological differences between early- and late-onset PsA and PsO. Herein, we review the effect of age in patients with PsD, with a focus on PsA, highlighting the need to consider this factor in routine clinical practice as well as in research.<\/jats:p>","DOI":"10.3899\/jrheum.210349","type":"journal-article","created":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T09:05:11Z","timestamp":1629018311000},"page":"1085-1091","source":"Crossref","is-referenced-by-count":30,"title":["Does Age Matter in Psoriatic Arthritis? A Narrative Review"],"prefix":"10.3899","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-3726","authenticated-orcid":false,"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7311","authenticated-orcid":false,"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2021,8,15]]},"reference":[{"key":"2025081722551393000_49.10.1085.1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025081722551393000_49.10.1085.2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0670"},{"key":"2025081722551393000_49.10.1085.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121500"},{"key":"2025081722551393000_49.10.1085.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201194"},{"key":"2025081722551393000_49.10.1085.5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23333","article-title":"Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study","volume":"70","author":"Ballegaard","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025081722551393000_49.10.1085.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu264"},{"key":"2025081722551393000_49.10.1085.7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-7-269"},{"key":"2025081722551393000_49.10.1085.8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2016.1139453","article-title":"Psoriatic arthritis: complexities, comorbidities and implications for the clinic","volume":"12","author":"Haroon","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"2025081722551393000_49.10.1085.9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.det.2014.09.003","article-title":"Psoriasis and the life cycle of persistent life effects","volume":"33","author":"Garshick","year":"2015","journal-title":"Dermatol Clin"},{"key":"2025081722551393000_49.10.1085.10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/17469872.3.2.133","article-title":"Comorbidities in Psoriatic disease","volume":"2","author":"Gulliver","year":"2008","journal-title":"Expert Rev Dermatol"},{"key":"2025081722551393000_49.10.1085.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150757"},{"key":"2025081722551393000_49.10.1085.12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaad.2017.03.037","article-title":"Real-world burden of comorbidities in US patients with psoriasis","volume":"77","author":"Shah","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025081722551393000_49.10.1085.13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.rdc.2015.07.008","article-title":"Comorbidities in psoriatic arthritis","volume":"41","author":"Husni","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2025081722551393000_49.10.1085.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1692-7"},{"key":"2025081722551393000_49.10.1085.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22492"},{"key":"2025081722551393000_49.10.1085.16","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/acr.20627","article-title":"Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis","volume":"63","author":"Husted","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2025081722551393000_49.10.1085.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2743-7"},{"key":"2025081722551393000_49.10.1085.18","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.297"},{"key":"2025081722551393000_49.10.1085.19","first-page":"182","article-title":"Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis","volume":"32","author":"Favarato","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025081722551393000_49.10.1085.20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","article-title":"Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study","volume":"19","author":"Bengtsson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025081722551393000_49.10.1085.21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","article-title":"Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis","volume":"21","author":"Li","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"2025081722551393000_49.10.1085.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"2025081722551393000_49.10.1085.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210275"},{"key":"2025081722551393000_49.10.1085.24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","article-title":"The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events","volume":"77","author":"Egeberg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025081722551393000_49.10.1085.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735"},{"key":"2025081722551393000_49.10.1085.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210390"},{"key":"2025081722551393000_49.10.1085.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205267"},{"key":"2025081722551393000_49.10.1085.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07986.x"},{"key":"2025081722551393000_49.10.1085.29","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12742"},{"key":"2025081722551393000_49.10.1085.30","first-page":"122","article-title":"Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data","volume":"25","author":"Kaine","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2025081722551393000_49.10.1085.31","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/bjd.14833","article-title":"Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting","volume":"176","author":"Lamb","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025081722551393000_49.10.1085.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130797"},{"key":"2025081722551393000_49.10.1085.33","first-page":"318","article-title":"Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA)","volume":"31","author":"Bandinelli","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025081722551393000_49.10.1085.34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13075-017-1265-5","article-title":"Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis","volume":"19","author":"Bergman","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025081722551393000_49.10.1085.35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/1346-8138.13157","article-title":"Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: results from the ARIZONA study","volume":"43","author":"Lopez-Estebaranz","year":"2016","journal-title":"J Dermatol"},{"key":"2025081722551393000_49.10.1085.36","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.186"},{"key":"2025081722551393000_49.10.1085.37","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799001452"},{"key":"2025081722551393000_49.10.1085.38","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2003.02056.x"},{"key":"2025081722551393000_49.10.1085.39","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2001.00130.x"},{"key":"2025081722551393000_49.10.1085.40","doi-asserted-by":"publisher","DOI":"10.2307\/2137349"},{"key":"2025081722551393000_49.10.1085.41","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12294"},{"key":"2025081722551393000_49.10.1085.42","first-page":"S85","article-title":"Use of MTX in the elderly and in patients with compromised renal function","volume":"5","author":"Morgacheva","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2025081722551393000_49.10.1085.43","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.051144"},{"key":"2025081722551393000_49.10.1085.44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00002512-200926050-00003","article-title":"Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment","volume":"26","author":"Alivernini","year":"2009","journal-title":"Drugs Aging"},{"key":"2025081722551393000_49.10.1085.45","first-page":"234","article-title":"Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis","volume":"33","author":"Bathon","year":"2006","journal-title":"J Rheumatol"},{"key":"2025081722551393000_49.10.1085.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.22688"},{"key":"2025081722551393000_49.10.1085.47","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200218"},{"key":"2025081722551393000_49.10.1085.48","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094730"},{"key":"2025081722551393000_49.10.1085.49","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200724030-00005"},{"key":"2025081722551393000_49.10.1085.50","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s10067-017-3697-3","article-title":"Elderly psoriatic arthritis patients on TNF-\u03b1 blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate","volume":"36","author":"Costa","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025081722551393000_49.10.1085.51","doi-asserted-by":"publisher","DOI":"10.1159\/000345623"},{"key":"2025081722551393000_49.10.1085.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.040"},{"key":"2025081722551393000_49.10.1085.53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2006.02.010","article-title":"Etanercept for the treatment of psoriasis in the elderly","volume":"55","author":"Militello","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2025081722551393000_49.10.1085.54","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.214585"},{"key":"2025081722551393000_49.10.1085.55","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2147\/JIR.S282691","article-title":"Effect of biologics on cardiovascular inflammation: mechanistic insights and risk reduction","volume":"14","author":"Fragoulis","year":"2021","journal-title":"J Inflamm Res"},{"key":"2025081722551393000_49.10.1085.56","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.131359"},{"key":"2025081722551393000_49.10.1085.57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025081722551393000_49.10.1085.58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies","volume":"35","author":"Korber","year":"2018","journal-title":"Drugs Aging"},{"key":"2025081722551393000_49.10.1085.59","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1346-8138.12653","article-title":"Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis","volume":"41","author":"Hayashi","year":"2014","journal-title":"J Dermatol"},{"key":"2025081722551393000_49.10.1085.60","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ced.12850","article-title":"Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period","volume":"41","author":"Megna","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"2025081722551393000_49.10.1085.61","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025081722551393000_49.10.1085.62","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000546"},{"key":"2025081722551393000_49.10.1085.63","first-page":"390","article-title":"Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025081722551393000_49.10.1085.64","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"2025081722551393000_49.10.1085.65","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080691"},{"key":"2025081722551393000_49.10.1085.66","doi-asserted-by":"crossref","first-page":"e7833","DOI":"10.1097\/MD.0000000000007833","article-title":"Characteristics of Turkish patients with elderly onset psoriatic arthritis: a retrospective cohort study","volume":"96","author":"Kobak","year":"2017","journal-title":"Medicine"},{"key":"2025081722551393000_49.10.1085.67","doi-asserted-by":"publisher","DOI":"10.1016\/S0531-5565(01)00211-X"},{"key":"2025081722551393000_49.10.1085.68","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.4.226"},{"key":"2025081722551393000_49.10.1085.69","first-page":"476","article-title":"Patients with psoriatic arthritis may show differences in their clinical and genetic profiles depending on their age at psoriasis onset","volume":"30","author":"Queiro","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2025081722551393000_49.10.1085.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.11.005"},{"key":"2025081722551393000_49.10.1085.71","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.2027"},{"key":"2025081722551393000_49.10.1085.72","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.semarthrit.2018.08.005","article-title":"Late onset psoriatic arthritis in a longitudinal cohort: disease presentation, activity over time and prognosis","volume":"48","author":"Polachek","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025081722551393000_49.10.1085.73","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401021"},{"key":"2025081722551393000_49.10.1085.74","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000478012","article-title":"Autoimmunity in the elderly: insights from basic science and clinics \u2013 a mini-review","volume":"63","author":"Watad","year":"2017","journal-title":"Gerontology"},{"key":"2025081722551393000_49.10.1085.75","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-009-8169-3"},{"key":"2025081722551393000_49.10.1085.76","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjd.15035","article-title":"Is late-onset psoriasis a distinct subtype of chronic plaque psoriasis?","volume":"175","author":"Kirby","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025081722551393000_49.10.1085.77","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120470"},{"key":"2025081722551393000_49.10.1085.78","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjd.14886","article-title":"Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation","volume":"175","author":"Theodorakopoulou","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025081722551393000_49.10.1085.79","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bjd.13340","article-title":"Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions","volume":"172","author":"Hebert","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025081722551393000_49.10.1085.80","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/jid.2013.485","article-title":"Polymorphisms in IL-1B distinguish between psoriasis of early and late onset","volume":"134","author":"Hebert","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2025081722551393000_49.10.1085.81","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jdv.12850","article-title":"Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis","volume":"30","author":"Phan","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025081722551393000_49.10.1085.82","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/bjd.13865","article-title":"Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis","volume":"173","author":"Griffiths","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025081722551393000_49.10.1085.83","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjd.12371","article-title":"Psychological differences between early- and late-onset psoriasis: a study of personality traits, anxiety and depression in psoriasis","volume":"169","author":"Remrod","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025081722551393000_49.10.1085.84","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/pde.12416","article-title":"Effect of age at diagnosis on chronic quality of life and long-term outcomes of individuals with psoriasis","volume":"32","author":"Kim","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"2025081722551393000_49.10.1085.85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-4632.2011.04979.x","article-title":"Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype?","volume":"51","author":"Kwon","year":"2012","journal-title":"Int J Dermatol"},{"key":"2025081722551393000_49.10.1085.86","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1759720X18783894","article-title":"Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review","volume":"10","author":"Nikiphorou","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025081722551393000_49.10.1085.87","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130457"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.210349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T05:55:40Z","timestamp":1755496540000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.210349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,15]]},"references-count":87,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,1]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.3899\/jrheum.210349"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.210349","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,15]]}}}